Shares of OXiGENE Inc. (NASDAQ:OXGN) traded down 5.87% during mid-day trading on Tuesday, hitting $4.01. The stock had a trading volume of 1,741,064 shares. OXiGENE has a 1-year low of $1.96 and a 1-year high of $5.40. The stock’s 50-day moving average is $2.50 and its 200-day moving average is $2.60. The company’s market cap is $12.6 million. OXiGENE also was the target of a large decrease in short interest in the month of January. As of February 28th, there was short interest totalling 249,652 shares, a decrease of 58.6% from the February 14th total of 603,743 shares. Based on an average trading volume of 587,940 shares, the short-interest ratio is presently 0.4 days. Approximately 2.4% of the shares of the stock are short sold. OXiGENE Inc (NASDAQ:OXGN) shares after opening at $2.78 moved to $3.10 on last trade day and at the end of the day closed at $2.98. Company price to sales ratio in past twelve months was calculated as 454.45 and price to cash ratio as 5.16. OXiGENE Inc (NASDAQ:OXGN) showed a negative weekly performance of -14.86%.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) announced the availability of HETLIOZ™. HETLIOZ™ is the first treatment approved by the U.S Food and Drug Administration (FDA) for Non-24-Hour Sleep-Wake Disorder (Non-24), a serious chronic circadian rhythm disorder that affects up to 70 percent of people who are totally blind. Vanda has launched HETLIOZ Solutions™ to support and facilitate the treatment of totally blind people living with Non-24. HETLIOZ Solutions™ will provide patients with a host of resources including information about Non-24 and HETLIOZ™, insurance support, overview of financial assistance programs, and pharmacy access. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares advanced 4.06% in last trading session and ended the day on $13.85. VNDA return on equity ratio is recorded as -76.90% and its return on assets is -15.00%. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) yearly performance is 205.74%.
Idera Pharmaceuticals Inc (NASDAQ:IDRA) presented new preclinical data demonstrating the ability of its Toll-like receptor (TLR) antagonist, IMO-8400, to inhibit the survival and proliferation of B-cell lymphoma cells harboring the oncogenic MYD88 L265P genetic mutation. These data add to the growing body of research which supports the Company’s efforts to develop IMO-8400 for the treatment of genetically defined forms of B-cell lymphoma. The findings were presented in a poster session titled “Immune Modulatory Agents and Interventions” at the 2014 American Association for Cancer Research (AACR) Annual Meeting in San Diego, California. Idera Pharmaceuticals Inc (NASDAQ:IDRA) shares moved up 10.52% in last trading session and was closed at $2.94, while trading in range of $ 2.61 – 3.00. Idera Pharmaceuticals Inc (NASDAQ:IDRA) year to date (YTD) performance is -36.50%.
Analysts at Canaccord Genuity began coverage on shares of Immunogen (NASDAQ:IMGN) in a research report issued to clients and investors on Wednesday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $20.00 price target on the stock. Canaccord Genuity’s price target points to a potential upside of 56.25% from the stock’s previous close. ImmunoGen, Inc. (NASDAQ:IMGN) weekly performance is -3.60%. On last trading day company shares ended up $14.21. ImmunoGen, Inc. (NASDAQ:IMGN) distance from 50-day simple moving average (SMA50) is -8.28%. Analysts mean target price for the company is $16.95.
Leave a Reply